Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Beyond the global brain differences: Intraindividual variability differences in 1q21.1 distal and 15q11.2 BP1-BP2 deletion carriers

  • Boen, Rune
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
Rune Boen, et al., [Background]: Carriers of the 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants exhibit regional and global brain differences compared with noncarriers. However, interpreting regional differences is challenging if a global difference drives the regional brain differences. Intraindividual variability measures can be used to test for regional differences beyond global differences in brain structure., [Methods]: Magnetic resonance imaging data were used to obtain regional brain values for 1q21.1 distal deletion (n = 30) and duplication (n = 27) and 15q11.2 BP1-BP2 deletion (n = 170) and duplication (n = 243) carriers and matched noncarriers (n = 2350). Regional intra-deviation scores, i.e., the standardized difference between an individual's regional difference and global difference, were used to test for regional differences that diverge from the global difference., [Results]: For the 1q21.1 distal deletion carriers, cortical surface area for regions in the medial visual cortex, posterior cingulate, and temporal pole differed less and regions in the prefrontal and superior temporal cortex differed more than the global difference in cortical surface area. For the 15q11.2 BP1-BP2 deletion carriers, cortical thickness in regions in the medial visual cortex, auditory cortex, and temporal pole differed less and the prefrontal and somatosensory cortex differed more than the global difference in cortical thickness., [Conclusions]: We find evidence for regional effects beyond differences in global brain measures in 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants. The results provide new insight into brain profiling of the 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants, with the potential to increase understanding of the mechanisms involved in altered neurodevelopment., 1000BRAINS. This work was supported by the Institute of Neuroscience and Medicine (INM-1), Research Centre Julich, European Union’s Horizon 2020 Research and Innovation Programme (Grant No. 945539 [HBP SGA3; SC]), and Joint Lab Supercomputing and Modeling for the Human Brain. We thank the Heinz Nixdorf Foundation for the generous support of the Heinz Nixdorf Study. We also thank the scientists and the study staff of the Heinz Nixdorf Recall Study and 1000BRAINS. We gratefully acknowledge the computing time granted through JARA-HPC on the supercomputer JURECA at Forschungszentrum Julich. TOP: This work was supported by Research Council of Norway (Grant Nos. 23273 (Centre of Excellence, Norwegian Centre for Mental Disorders, NORMENT), Grant Nos. 324252 and 226971). ENIGMA-CNV Working Group. This work was supported by the Research Council of Norway (Grant No. 223273 [to OAA]), South-Eastern Norway Regional Health Authority (Grant No. 2020060 [to IES, RB]), European Union’s Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant No. 847776 [to IES]), Kristian Gerhard Jebsen Stiftelsen (Grant No. SKGJ-MED-021 [to IES]), and National Institute of Mental Health (NIMH) (Grant Nos. U01MH119736, R21MH116473, R01MH085953 [to CEB]), and 1R01MH129858-01A1 [to SJ]. This work was performed on Services for Sensitive Data, University of Oslo, with resources provided by UNINETT Sigma2, the national infrastructure for high performance computing and data storage in Norway. Australian Schizophrenia Research Bank: This work was supported by the Australian National Health and Medical Research Council (NHMRC) (Enabling Grant No. 386500, L3 Investigator Grant No. 1196508 [to CP]), and Program Grant No. APP1150083 [to CP]), Pratt Foundation, Ramsay Health Care, Viertel Charitable Foundation, and Schizophrenia Research Institute. Chief Investigators for the Australian Schizophrenia Research Bank were Vaughan Carr, US, RJS, Assen Jablensky, BJM, Patricia Michie, Stanley Catts, FAH, and CP. ECHO-DEFINE: This work was supported by the Wellcome Trust (Institutional Strategic Support Fund [to MBMvdB] and Clinical Research Training Fellowship Grant No. 102003/Z/13/Z [to JLD]), Waterloo Foundation (Grant No. WF 918-1234 [to MBMvdB]), Baily Thomas Charitable Fund (Grant No. 2315/1 [to MBMvdB]), NIMH (Grant Nos. 5UO1MH101724 and U01MH119738 [to MBMvdB]), IMAGINE-ID and IMAGINE-2 studies (funded by Medical Research Council Grant Nos. MR/N022572/1 and MR/T033045/1 [to MBMvdB]), and Medical Research Council (Centre Grant No. MR/P005748/1 [to MJO]). The DEFINE study was supported by a Wellcome Trust Strategic Award (Grant No. 100202/Z/12/Z [to MJO]). FOR2107 Marburg and Münster: This work is part of the German multicenter consortium “Neurobiology of Affective Disorders: A Translational Perspective on Brain Structure and Function,” supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; Forschungsgruppe/Research Unit FOR2107). Principal investigators with respective areas of responsibility in the FOR2107 consortium: Work Package WP1, FOR2107/MACS cohort and brainimaging: TK (speaker FOR2107; DFG Grant Nos. KI 588/14-1, KI 588/14-2, KI 588/20-1, and KI 588/22-1), UD (co-speaker FOR2107; Grant Nos. DA 1151/5-1, DA 1151/5-2, and DA 1151/6-1), Axel Krug (Grant Nos. KR 3822/5-1 and KR 3822/7-2), IN (Grant Nos. NE 2254/1-2, NE 2254/3-1, and NE 2254/4-1), Carsten Konrad (Grant No. KO 4291/3-1). WP5, genetics: Marcella Rietschel (Grant Nos. RI 908/11-1 and RI 908/11-2), MMN (Grant Nos. NO 246/10-1 and NO 246/10-2), Stephanie Witt (Grant Nos. WI 3439/3-1 and WI 3439/3-2). WP6, multi-method data analytics: AJ (Grant Nos. JA 1890/7-1 and JA 1890/7-2), TH (Grant No. HA 7070/2-2). We are deeply indebted to all study participants and staff. A list of acknowledgments can be found at: www.for2107.de/acknowledgements. UCLA-Utrecht: This work was supported by the NIMH (Grant No. R01 MH090553 [to RAO]). The NIMH had no further role in study design, in the collection, analysis, and interpretation of the data, in the writing of the report, and in the decision to submit the paper for publication. QTIM: This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant No. R01 HD050735) and the NHMRC (Grant Nos. 486682 and 1009064). Genotyping was supported by the NHMRC (Grant No. 389875). BETULA: This work was supported by the Knut and Alice Wallenberg Foundation (scholar grant [to LN]). Freesurfer calculations were enabled by resources provided by the Swedish National Infrastructure for Computing at HPC2N, Umeå. SHIP (Study of Health in Pomerania): This work is part of the Community Medicine Research net of the University of Greifswald, Germany, which is supported by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), Ministry of Cultural Affairs, and Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data in SHIP have been supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012) and a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. PAFIP (Programa de Atención a las Fases Iniciales de Psicosis): This work was supported by the Instituto de Salud Carlos III (Grant Nos. 00/3095, 01/3129, PI020499, PI14/00639, PI17/01056, and PI14/00918), SENY Fundació (Research Grant No. CI2005 0308007), and Fundación Marqués de Valdecilla Instituto de Investigación Sanitaria Valdecilla (Grant Nos. A/02/07, NCT0235832, and NCT02534363). Osaka: This work was supported by the Japan Agency for Medical Research and Development (Grant Nos. JP21wm0425012, JP18dm0307002, JP22wm0525019, and JP22dk0207060) and Japan Society for the Promotion of Science KAKENHI (Grant Nos. JP20H03611, JP22H04926, and 20K15778). Some computations were performed at the Research Center for Computational Science, Okazaki, Japan (Project: NIPS, 18-IMS-C162, 19-IMS-C181, 20-IMS-C162, 21-IMS-C179, 22-IMS-C195). IMAGEN: This work was supported by the European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-Related Behavior in Normal Brain Function and Psychopathology) (Grant No. LSHM-CT-2007-037286), Horizon 2020–funded ERC Advanced Grant STRATIFY (Brain Network Based Stratification of Reinforcement-Related Disorders) (Grant No. 695313), Medical Research Foundation and Medical Research Council (Grants Nos. MR/R00465X/1 and MRF-058-0004-RG-DESRI [Neurobiological Underpinning of Eating Disorders: Integrative Biopsychosocial Longitudinal Analyses in Adolescents] and MR/S020306/1 and MRF-058-0009-RG-DESR-C0759 [Establishing Causal Relationships Between Biopsychosocial Predictors and Correlates of Eating Disorders and Their Mediation by Neural Pathways]), National Institutes of Health (NIH) (Consortium Grant No. U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence, and Grant No. 1R56AG058854-01), National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, ERANID (Understanding the Interplay Between Cultural, Biological and Subjective Factors in Drug Use Pathways) (Grant No. PR-ST-0416-10004), BRIDGET (JPND: BRain Imaging, cognition Dementia and next generation GEnomics) (Grant No. MR/N027558/1), Human Brain Project (HBP SGA 2) (Grant No. 785907), FP7 project MATRICS (Grant No. 603016), Medical Research Council Grant Consortium on Vulnerability to Externalizing Disorders and Addictions (Grant No. MR/N000390/1), Bundesministerium für Bildung und Forschung (Grant Nos. 01GS08152, 01EV0711, Forschungsnetz AERIAL 01EE1406A, and 01EE1406B), Deutsche Forschungsgemeinschaft (Grant Nos. SM 80/7-2, SFB 940/2, and NE 1383/14-1), Agence Nationale de la Recherche (ANR) (Grant Nos. ANR-12-SAMA-0004 and AAPG2019 [GeBra]), Eranet Neuron (Grant Nos. AF12-NEUR0008-01 [WM2NA], ANR-18-NEUR00002-01 [ADORe], and ANR-12-SAMA-0004), Fondation de France (Grant No. 00081242), Fondation pour la Recherche Médicale (Grant No. DPA20140629802), Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives, Assistance Publique Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale (Interface Grant), Paris Sud University IDEX 2012, Fondation de l’Avenir (Grant No. AP-RM-17-013), and Fédération pour la Recherche sur le Cerveau. MCIC (Mind Clinical Imaging Consortium): This work was supported by the NIH (NIH/National Center for Research Resources Grant No. P41RR14075 [to VC] and Grant No. R01EB005846 [to VC]), Department of Energy (Grant No. DE-FG02-99ER62764), Mind Research Network, Morphometry Biomedical Informatics Research Network (Grant Nos. 1U24 and RR021382A), Function Biomedical Informatics Research Network (Grant No. U24RR021992-01 [to VC], NIH/National Center for Research Resources Grant No. MO1 RR025758-01 [to VC], and NIMH Grant No. 1RC1MH089257 [to VC]), Deutsche Forschungsgemeinschaft (research fellowship [to SE]), and Brain and Behavior Research Foundation (NARSAD Young Investigator Award [to SE]). NTR (Netherlands Twin Register): This work was supported by the Netherlands Organization for Scientific Research (NWO) and Netherlands Organisation for Health Research and Development (Grant Nos. 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004,463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity programme—024.001.003, and NWO-Groot 480-15-001/674), Center for Medical Systems Biology (NWO Genomics), NBIC/BioAssist/RK (Grant No. 2008.024), Biobanking and Biomolecular Resources Research Infrastructure The Netherlands (Grant Nos. 184.021.007 and 184.033.111), Spinozapremie (Grant No. NWO-56-464-14192), Royal Netherlands Academy of Arts and Sciences Academy Professor Award (Grant No. PAH/6635) and University Research Fellow grant (to DIB), Amsterdam Public Health research institute (former EMGO+ Institute for Health and Care Research), Amsterdam Neuroscience (former Neuoscience Campus Amsterdam), European Science Foundation (Grant No. EU/QLRT-2001-01254), European Community’s Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, Grant Nos. 01413: ENGAGE and 602768: ACTION), European Research Council (Grant Nos. ERC Starting 284167, ERC Consolidator 771057, and ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH Grant No. U24 MH068457-06), NIH (Grant Nos. R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, and R01 DK092127-04 and Grand Opportunity Grant Nos. 1RC2 MH089951 and 1RC2 MH089995), and Avera Institute for Human Genetics. The genotyping and analyses were partly funded by the Genetic Association Information Network of the Foundation for the National Institutes of Health. Computing was supported by NWO (Grant No. 2018/EW/00408559), BiG Grid, Dutch e-Science Grid, and SURFsara. OATS (Older Australian Twins Study): This work was supported by the NHMRC and Australian Research Council Strategic Award Grant of the Ageing Well, Ageing Productively Program (Grant No. 401162), NHMRC project (seed) grants (Grant Nos. 1024224 and 1025243), NHMRC project grants (Grant Nos. 1045325 and 1085606), and NHMRC program grants (Grant Nos. 568969 and 1093083). The OATS Study was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (Grant No. 1079102) from the NHMRC. We thank the participants for their time and generosity in contributing to this research. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. PING (Pediatric Imaging, Neurocognition, and Genetics): This work was supported by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant Nos. RC2DA029475 and R01 HD061414). EPIGEN-London/University College London: The work was partly undertaken at University College London Hospitals NHS Foundation Trust/University College London, which received a proportion of funding from the UK Department of Health National Institute for Health Research Biomedical Research Centres funding scheme. We thank the Wolfson Trust and the Epilepsy Society for supporting the Epilepsy Society MRI scanner. OSR (Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffele)-Milan: This work was supported by the European Union H2020 (EU.3.1.1 Grant No. 754740 MOODSTRATIFICATION.EU), Italian Ministry of Health (Grant No. RF-2018-12367249) and Italian Ministry of University and Scientific Research (Grant No. A_201779W93T). Dublin: This work was supported by the European Research Council (Grant No. ERC-2015-STG-677467 [to GD]) and Science Foundation Ireland (Grant No. SFI-16/ERCS/3787 [to GD]). Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, the Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers from the Donders Centre for Cognitive Neuroimaging, Human Genetics and Cognitive Neuroscience departments of Radboud University Medical Centre, and Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative is supported by the participating departments and centers and Biobanking and Biomolecular Resources Research Infrastructure (Netherlands), Hersenstichting Nederland, and NWO. The research leading to these results also receives funding from the NWO (Gravitation Grant No. 024.001.006 Language in Interaction), European Community’s Seventh Framework Programme (FP7/2007-2013) (Grant Nos. 602450 IMAGEMEND, 278948 TACTICS, and 602805 Aggressotype), European Community’s Horizon 2020 programme (Grant Nos. 643051 MiND, and ERC-2010-AdG 268800-NEUROSCHEMA). In addition, the work was supported by the ENIGMA Consortium (Grant No. U54 EB020403) from the BD2K Initiative of a cross-NIH partnership. UK Biobank: This research has been conducted using the UK Biobank Resource under Application Number 27412. OAA has received speaker’s honorarium from Lundbeck, Janssen, and Sunovion and is a consultant to Coretechs.ai. TRM reports personal fees from Pfizer, Lundbeck, Astellas, Janssen, and Angelini outside the submitted work. He is an employee and shareholder of Pasithea Therapeutics. CRKC has received partial research support from Biogen for work unrelated to the topic of this article (principal investigator, PMT). PMT has received partial research support from Biogen for work unrelated to the topic of this article. MBMvdB and MJO report grants from Takeda Pharmaceuticals outside the submitted work. MJO reports a grant from Akrivia Health outside the submitted work. HJG has received travel grants and speaker’s honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen as well as research funding from Fresenius Medical Care. GS has received honoraria for participating at advisory board meetings from Roche and Biogen regarding new Alzheimer’s disease drugs. KKS has received consultant and speaker’s honoraria from Roche and OrionPharma, reimbursement of travel and accommodation costs at a meeting from Kolpharma, and sponsorships for arranging conferences from Desitin and Eisai AB. IG has received speaker’s honorarium from Lundbeck. MMN has received fees for membership in an advisory board from HMG Systems Engineering GmbH, for membership in the Medical-Scientific Editorial Office of the Deutsches Ärzteblatt, and for serving as a consultant for Everis Belgium in a project of the European Commission (REFORM/SC2020/029). MMN also receives salary payments from Life & Brain GmbH and holds shares in Life & Brain GmbH. All these concerned activities outside the submitted work. CP received honoraria for talks from Lundbeck, Australia Pty Ltd. outside the submitted work. DJS has received consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, L’Oreal, Lundbeck, Orion, Sanofi, Servier, Takeda and Vistagen. JH has received speaker’s honorarium from Medice and Takeda outside the submitted work. KP reports work with Novo Nordisk and Roche clinical trials outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differences in total and differential white blood cell counts and in inflammatory parameters between psychiatric inpatients with and without recent consumption of cannabinoids, opioids, or cocaine: A retrospective single-center study

  • Llorca-Bofí, Vicent
  • Mur, Maria
  • Font Font, Maria
  • Palacios Garrán, Roberto
  • Sellart, Maite
  • del Agua, Enrique
  • Arteaga-Henriquez, Gara
Cannabinoids; Inflammation; Neutrophils, Cannabinoides; Inflamació; Neutròfils, Cannabinoides; Inflamación; Neutrófilos, Several drugs of abuse may exert their action by modulating the immune system. Despite this, individuals using substances of abuse are often excluded from immunopsychiatry studies. We conducted a retrospective, single-center study to examine differences in circulating immune/inflammatory parameters (i.e., total and differential white blood cell (WBC) counts, neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte (MLR) ratio, platelet-to-lymphocyte ratio, and C-reactive protein) between psychiatric inpatients with a positive urine test to cannabinoids, opioids, or cocaine, and those with negative toxicology. A total of 927 inpatients were included. Patients with positive toxicology (n = 208) had significantly higher WBC counts (P < 0.001, η2p = 0.02), as well as increased neutrophils (P = 0.002, η2p = 0.01), monocytes (P < 0.001, η2p = 0.02), lymphocytes (P < 0.001, η2p = 0.02), and eosinophils (P = 0.01, η2p = 0.01) compared to those with negative toxicology (n = 719). The increase in neutrophil counts was particularly evident in patients who tested positive for cannabinoids (n = 168; P < 0.001, η2p = 0.02). In contrast, eosinophil counts were particularly increased in the cocaine-positive subgroup (n = 27; P = 0.004, η2p = 0.01). Patients with a positive urine test to opioids (n = 13) were characterized by a significantly lower MLR (P = 0.03, η2p = 0.005). The type of psychiatric diagnosis moderated the differences in neutrophil counts between patients with a positive and negative toxicology to cannabinoids. Notably, significantly higher neutrophil counts were found only in patients diagnosed with a psychotic disorder (P < 0.001, η2p = 0.03). Taken together, our findings suggest that drugs of abuse may differently impact the immune/inflammatory response system in individuals diagnosed with psychiatric conditions. Specifically, recent cannabinoids use may be associated with an acute activation of the inflammatory response system, particularly in individuals with a psychotic disorder, while cocaine and opioid use may be associated with eosinophilia and a decrease in the MLR, respectively, regardless of the primary psychiatric diagnosis., GA-H was supported by the European Commission, and funded by the European's Union Horizon 2020 research and innovation program under grant agreement numbers 728018 and 754740.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Differences in total and differential white blood cell counts and in inflammatory parameters between psychiatric inpatients with and without recent consumption of cannabinoids, opioids, or cocaine: A retrospective single-center study

  • Llorca-Bofí, Vicent
  • Mur, Maria
  • Font Font, Maria
  • Palacios Garrán, Roberto
  • Sellart, Maite
  • del Agua, Enrique
  • Arteaga-Henriquez, Gara
Cannabinoids; Inflammation; Neutrophils, Cannabinoides; Inflamació; Neutròfils, Cannabinoides; Inflamación; Neutrófilos, Several drugs of abuse may exert their action by modulating the immune system. Despite this, individuals using substances of abuse are often excluded from immunopsychiatry studies. We conducted a retrospective, single-center study to examine differences in circulating immune/inflammatory parameters (i.e., total and differential white blood cell (WBC) counts, neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte (MLR) ratio, platelet-to-lymphocyte ratio, and C-reactive protein) between psychiatric inpatients with a positive urine test to cannabinoids, opioids, or cocaine, and those with negative toxicology. A total of 927 inpatients were included. Patients with positive toxicology (n = 208) had significantly higher WBC counts (P < 0.001, η2p = 0.02), as well as increased neutrophils (P = 0.002, η2p = 0.01), monocytes (P < 0.001, η2p = 0.02), lymphocytes (P < 0.001, η2p = 0.02), and eosinophils (P = 0.01, η2p = 0.01) compared to those with negative toxicology (n = 719). The increase in neutrophil counts was particularly evident in patients who tested positive for cannabinoids (n = 168; P < 0.001, η2p = 0.02). In contrast, eosinophil counts were particularly increased in the cocaine-positive subgroup (n = 27; P = 0.004, η2p = 0.01). Patients with a positive urine test to opioids (n = 13) were characterized by a significantly lower MLR (P = 0.03, η2p = 0.005). The type of psychiatric diagnosis moderated the differences in neutrophil counts between patients with a positive and negative toxicology to cannabinoids. Notably, significantly higher neutrophil counts were found only in patients diagnosed with a psychotic disorder (P < 0.001, η2p = 0.03). Taken together, our findings suggest that drugs of abuse may differently impact the immune/inflammatory response system in individuals diagnosed with psychiatric conditions. Specifically, recent cannabinoids use may be associated with an acute activation of the inflammatory response system, particularly in individuals with a psychotic disorder, while cocaine and opioid use may be associated with eosinophilia and a decrease in the MLR, respectively, regardless of the primary psychiatric diagnosis., GA-H was supported by the European Commission, and funded by the European's Union Horizon 2020 research and innovation program under grant agreement numbers 728018 and 754740.